October 30, 2023 11:01 AM EDT
News Briefing

Vyne aims to raise $88M; Sanofi in­vests in gene ther­a­py com­pa­ny; 4DMT ad­dress­es clin­i­cal hold

Ayisha Sharma

News Reporter

Lei Lei Wu

News Reporter

Jaimy Lee

Deputy Editor

Plus, news about Unit­ed Ther­a­peu­tics and Mod­er­na:

Im­muno-in­flam­ma­tion biotech’s $88M: Vyne Ther­a­peu­tics an­nounced an $88 mil­lion pri­vate place­ment to, in part …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Im­munol­o­gy biotech In­ma­gene to join Nas­daq through re­verse merg­er with what's left of Ike­na

A service from the Financial Times